Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holger Hebart

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
Leukemia|March 29, 2024
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Elza Lomaia, Christian Fabisch, et al.
Haematologica|July 16, 2013
Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopeniaAnne Rensing-Ehl, Ales Janda, Myriam R Lorenz, et al.
The Journal of Allergy and Clinical Immunology|November 18, 2023
Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencingAnne Rensing-Ehl, Myriam Ricarda Lorenz, Marita Führer, et al.
Leukemia|February 19, 2026
Development of a prognostic scoring system for chronic myeloid leukemia in blast phaseMichael Lauseker, Tomasz Sacha, Hana Klamova, et al.
The New England Journal of Medicine|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.
Blood|May 12, 2023
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.
Haematologica|December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IVChristian Michel, Andreas Burchert, Andreas Hochhaus, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
Leukemia|March 29, 2024
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Elza Lomaia, Christian Fabisch, et al.
Haematologica|July 16, 2013
Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopeniaAnne Rensing-Ehl, Ales Janda, Myriam R Lorenz, et al.
The Journal of Allergy and Clinical Immunology|November 18, 2023
Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencingAnne Rensing-Ehl, Myriam Ricarda Lorenz, Marita Führer, et al.
Leukemia|February 19, 2026
Development of a prognostic scoring system for chronic myeloid leukemia in blast phaseMichael Lauseker, Tomasz Sacha, Hana Klamova, et al.
The New England Journal of Medicine|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.
Blood|May 12, 2023
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.
Haematologica|December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IVChristian Michel, Andreas Burchert, Andreas Hochhaus, et al.
Pageof 7